Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotine Transdermal Patch for Cognitive Function in Schizophrenia
NCT05301660Phase 1Unknown
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Transdermal Patches, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of nicotine patch in schizophrenia (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Cognitive function of the subject, Negative and positive symptoms of the subject and 4 more. Status: unknown.
02
Drugs
nicotine patch
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05301660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05301660.